Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price was down 11.6% on Friday . The company traded as low as GBX 5.20 ($0.07) and last traded at GBX 5.20 ($0.07). Approximately 687,506 shares traded hands during mid-day trading, a decline of 1% from the average daily volume of 695,294 shares. The stock had previously closed at GBX 5.88 ($0.07).
Allergy Therapeutics Price Performance
The stock's 50 day simple moving average is GBX 5.05 and its 200 day simple moving average is GBX 4.84. The stock has a market capitalization of £262.35 million, a P/E ratio of -86.67, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Read More
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
